Supplementary Table 3 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

Monika Graeser; Oleg Gluz; Peter Schmid; Katarzyna Jóźwiak; Christine zu Eulenburg; Friedrich Feuerhake; Valery Volk; Daniel Ulbrich-Gebauer; Claudia Biehl; Mattea Reinisch; Kerstin Lüdtke-Heckenkamp; Andreas Daniel Hartkopf; Felix Hilpert; Michael Braun; Jens‐Uwe Blohmer; Matthias Christgen; Hans Heinrich Kreipe; Ulrike Anneliese Nitz; Enrico Pelz; Nadia Harbeck; Sherko Küemmel

doi:10.1158/1078-0432.31006915

Supplementary Table 3 from Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

2026 Open access

Read full text

Authors: Monika Graeser, Oleg Gluz, Peter Schmid, Katarzyna Jóźwiak, Christine zu Eulenburg, Friedrich Feuerhake, Valery Volk, Daniel Ulbrich-Gebauer, Claudia Biehl, Mattea Reinisch, Kerstin Lüdtke-Heckenkamp, Andreas Daniel Hartkopf

+9 more

Felix Hilpert, Michael Braun, Jens‐Uwe Blohmer, Matthias Christgen, Hans Heinrich Kreipe, Ulrike Anneliese Nitz, Enrico Pelz, Nadia Harbeck, Sherko Küemmel

DOI: 10.1158/1078-0432.31006915

Cited by: 0

Abstract

Supplementary Table 3. Selection of markers, development of scores, and associations with pCR.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies

Publication details

Publication date: 6 January 2026